Robert Davis, Merck CEO
July 7, 2022 06:59 AM EDT
Deals
Bioregnum

Fresh re­port of 'ad­vanced' $40B+ Seagen buy­out talks spurs more buzz about FTC show­down

Mer­ck CEO Rob Davis ap­pears com­mit­ted to push­ing through with a $40 bil­lion (or so) buy­out deal with Seagen, dri­ven by its need to be …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times